Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：9
|
作者：
Luger, Selina M. [1 ]
Sun, Zhuoxin [2 ]
Loghavi, Sanam [3 ]
Lazarus, Hillard M. [4 ]
Rowe, Jacob M. [5 ]
Tallman, Martin S. [6 ]
Pratz, Keith W. [7 ]
Litzow, Mark [8 ]
机构：
[1] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] ECOG ACRIN Stat Ctr, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[8] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128377
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1309
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase II Study of Midostaurin plus Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML)
    Reinhardt, Dirk
    Zwaan, Christian Michel
    Hoenekopp, Albert
    Niolat, Julie
    Ifrah, Sophie
    Noel-Baron, Florence
    Locatelli, Franco
    BLOOD, 2019, 134
  • [2] Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
    Abuasab, Tareq
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly S.
    Mohamed, Shehab Fareed
    Daver, Naval
    Kornblau, Steven M.
    Burger, Jan A.
    Jain, Nitin
    Islam, Rubiul
    DiNardo, Courtney D.
    Borthakur, Gautam
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [3] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
    Abuasab, Tareq
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Valero, Yesid Alvarado
    Daver, Naval Guastad
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly Sharon
    Kornblau, Steven Mitchell
    Burger, Jan Andreas
    Jain, Nitin
    Islam, Rabiul
    Dinardo, Courtney Denton
    Borthakur, Gautam
    Jabbour, Elias
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
    Arnan Sangerman, Montserrat
    Fernandez Moreno, Ainhoa
    Garcia Quintana, Antonio
    Garcia-Vidal, Carolina
    Olave Rubio, Maria Teresa
    Tormo Diaz, Maria Del Mar
    Vendranas, Meritxell
    Rodriguez Macias, Gabriela
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 203 - 214
  • [5] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
    Ong, Faustine
    Short, Nicholas
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Alvarado, Yesid
    Vaughan, Kenneth
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2022, 140 : 9029 - 9031
  • [6] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [7] Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive
    Garcia, J. S.
    Percival, M. E.
    DRUGS OF TODAY, 2017, 53 (10) : 531 - 543
  • [8] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia
    Sahoo, Ranjit K.
    Kumar, Lalit
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1901 - 1902
  • [9] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    Briski, Robert
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Valero, Yesid Alvarado
    Vaughan, Kenneth
    Pierce, Sherry
    Montalbano, Kathryn
    Mullin, Jillian
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2023, 142
  • [10] Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
    Stone, Richard M.
    Wang, Eunice S.
    Goldberg, Aaron David
    Sweet, Kendra Lynn
    Fathi, Amir Tahmasb
    Liu, Hongtao
    Messahel, Boo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345